| Zayar Phyo, Ko Ko, Serge Ouoba, Aya Sugiyama, Ulugbek Khudayberdievich Mirzaev, Golda Ataa Akuffo, Chanroth Chhoung, Tomoyuki Akita, Junko Tanaka Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis Journal Article In: PloS one, vol. 19, iss. 9, 2024, ISSN: 1932-6203. @article{Phyo2024,
title = {Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis},
author = {Zayar Phyo and Ko Ko and Serge Ouoba and Aya Sugiyama and Ulugbek Khudayberdievich Mirzaev and Golda Ataa Akuffo and Chanroth Chhoung and Tomoyuki Akita and Junko Tanaka},
url = {https://pubmed.ncbi.nlm.nih.gov/39298388/},
doi = {10.1371/JOURNAL.PONE.0307872},
issn = {1932-6203},
year = {2024},
date = {2024-01-01},
journal = {PloS one},
volume = {19},
issue = {9},
publisher = {PLoS One},
abstract = {Background Comprehensive details on Hepatitis C virus (HCV) infection in Myanmar are lacking. This study determined the prevalence of HCV antibodies and ribonucleic acid (RNA) and the distribution of HCV genotypes across different populations in Myanmar from 1990 to 2023. Material and methods A systematic search in PubMed, Web of Science, Scopus, and local journals identified studies reporting on HCV antibodies, RNA, and genotypes, excluding clinical research related to liver disease prognosis. Screening and data extraction was done by two authors and study populations were categorized into low-risk, high-risk, liver disease patients, and refugees outside the country. The pooled prevalence was performed by Dersimonian and Laird method using the R program. The publication bias was shown by funnel plot, the Egger test was used to assess the symmetry of the plot, and the heterogeneity was examined by the Cochran Q test and I2 index. Results Out of 135 reports screened for eligibility, 35 reports comprising 51 studies were included in which 33 studies provided data on HCV seroprevalence in 685,403 individuals, 8 studies reported HCV RNA prevalence in 25,018 individuals, and 10 studies examined HCV genotypes in 1,845 individuals. The pooled seroprevalence of HCV among low-risk, high-risk, liver disease patients and refugees were 2.18%, 37.07%, 33.84%, and 2.52% respectively. HCV RNA-positive rates in these groups were 1.40%, 5.25%, 24.96%, and 0.84% respectively. Seroprevalence studies showed publication bias (Egger test},
keywords = {doi:10.1371/journal.pone.0307872, Endemic Diseases, Genotype*, Hepacivirus* / genetics, Hepacivirus* / isolation \& purification, Hepatitis C* / epidemiology, Hepatitis C* / virology, Humans, Junko Tanaka, Ko Ko, MEDLINE, Meta-Analysis, Myanmar / epidemiology, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11412534, pmid:39298388, Prevalence, PubMed Abstract, RNA, Seroepidemiologic Studies, Systematic review, Viral / genetics, Zayar Phyo},
pubstate = {published},
tppubtype = {article}
}
Background Comprehensive details on Hepatitis C virus (HCV) infection in Myanmar are lacking. This study determined the prevalence of HCV antibodies and ribonucleic acid (RNA) and the distribution of HCV genotypes across different populations in Myanmar from 1990 to 2023. Material and methods A systematic search in PubMed, Web of Science, Scopus, and local journals identified studies reporting on HCV antibodies, RNA, and genotypes, excluding clinical research related to liver disease prognosis. Screening and data extraction was done by two authors and study populations were categorized into low-risk, high-risk, liver disease patients, and refugees outside the country. The pooled prevalence was performed by Dersimonian and Laird method using the R program. The publication bias was shown by funnel plot, the Egger test was used to assess the symmetry of the plot, and the heterogeneity was examined by the Cochran Q test and I2 index. Results Out of 135 reports screened for eligibility, 35 reports comprising 51 studies were included in which 33 studies provided data on HCV seroprevalence in 685,403 individuals, 8 studies reported HCV RNA prevalence in 25,018 individuals, and 10 studies examined HCV genotypes in 1,845 individuals. The pooled seroprevalence of HCV among low-risk, high-risk, liver disease patients and refugees were 2.18%, 37.07%, 33.84%, and 2.52% respectively. HCV RNA-positive rates in these groups were 1.40%, 5.25%, 24.96%, and 0.84% respectively. Seroprevalence studies showed publication bias (Egger test |
